Alamar Biosciences (ALMR) Stock Price, News & Analysis
Why is ALMR Stock Up Today?
AI-generated explanation by Rhea-AI. How Rhea-AI works. Not financial advice.
What Changed
Price Move History
- Daily moves over 5%
- 36 135 sessions, April 17, 2026 to October 28, 2026
- Largest daily move
- +30.7% close of August 11, 2026
- 1-month change
- +5.2% closing prices, September 28, 2026 to October 28, 2026
Company Description
Alamar Biosciences, Inc. develops proteomics technologies for protein detection and analysis. The company’s business centers on its NULISA technology, which stands for NUcleic Acid Linked Immuno-Sandwich Assay, and on a broader Precision Proteomics platform designed to detect and quantify protein biomarkers from small biofluid samples with high sensitivity and specificity.
Alamar sells instruments, consumables, and services based on its proteomic liquid biopsy platform. Its product portfolio includes NULISAseq panels, NULISAqpcr assays, and the ARGO HT fully automated, high-throughput system, which supports a sample-to-answer workflow. The company’s products are used in protein biomarker research, including applications tied to early disease detection and neurodegenerative disease research.
The company operates as a single-segment business focused on developing and commercializing protein-analysis tools. Its revenue model is tied to platform adoption, instrument sales, consumable usage, assay and panel offerings, and related services. Alamar’s customer base includes academic research institutions and biopharmaceutical organizations that use proteomics tools to study disease biology and biomarker signatures.
Alamar Biosciences is incorporated in Delaware and is headquartered in Fremont, California. Its common stock trades on the Nasdaq Stock Market under the symbol ALMR. The company completed its initial public offering in April 2026, after which it adopted amended and restated governing documents as a public company.
Stock Performance
Alamar Biosciences (ALMR) closed at $34.30 on October 28, 2026. Over the past month, the price has gained 5.2%.
ALMR Metrics & Rankings
Price returns through October 28, 2026. Month-to-date and YTD include the first trading day. Ranking links may use different dates.
Latest News
Alamar Biosciences has 10 recent news articles, with the latest published today. Of the recent coverage, 3 articles coincided with positive price movement and 6 with negative movement. Key topics include earnings date, management, earnings, partnership. View all ALMR news →
SEC Filings
Alamar Biosciences has filed 10 recent SEC filings, including 5 Form 4, 4 Form 144, 1 Form 3. The most recent filing was submitted on October 27, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all ALMR SEC filings →
Insider Radar
Insider selling at Alamar Biosciences over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.
Financial Highlights
Upcoming Events
Q3 2026 Results Release
Combined dataset completion
Alamar Biosciences has 2 upcoming scheduled events. The next event, "Q3 2026 Results Release", is scheduled for November 3, 2026 (in 6 days). 1 of them is an earnings release or call. Investors can track these dates to stay informed about potential catalysts that may affect the ALMR stock price.
Short Interest History
Short interest in Alamar Biosciences (ALMR) currently stands at 2.8 million shares, up 32.5% from the previous reporting period, representing 5.0% of the float. Since April 2026, short interest has increased by 143.8%.
Days to Cover History
Days to cover for Alamar Biosciences (ALMR) currently stands at 4.3 days, down 46.5% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since April 2026, the figure has increased by 187.2%. Across the settlements charted above, it has ranged from 1.5 to 11.5 days.
ALMR Company Profile & Sector Positioning
Alamar Biosciences (ALMR) operates in the Medical Devices industry within the broader Healthcare sector and is listed on the NASDAQ.
Alamar Biosciences (ALMR) announced Emory researchers identified a blood-protein signature that distinguished ALS patients from healthy controls with 98.3% balanced accuracy.
Published in Nature Communications, the study used Alamar’s NULISA technology to develop a 10-protein signature from 632 ALS patients and 160 healthy controls. Independent validation in 144 ALS patients and 37 controls showed 98.3% balanced accuracy versus 89.9% for neurofilament light chain alone, an established marker of nerve-fiber damage. The signature also identified some patients missed by that marker, including patients with relatively little disability. It remains a research finding, not a clinically validated screening or diagnostic test.